Sankei learned on Aug. 18 that the Tokyo Metropolitan Institute of Medical Science (TMIMS), which is affiliated with the Tokyo Metropolitan Government, is jointly developing a COVID-19 vaccine with a private pharmaceutical company and is preparing to start clinical trials. The vaccine’s efficacy in preventing the onset of COVID-19 was confirmed in non-clinical trials with mice and monkeys. The vaccine is expected to retain antibodies for a long time after one administration because it uses a smallpox vaccine that has been shown to maintain long-term immunity. TMIMS plans to start clinical trials in 2022 toward rapid implementation.
The vaccine that TMIMS and Nobelpharma are jointly developing combines DNA from the novel coronavirus and an attenuated form of the smallpox vaccine. They began development in April 2020 and conducted non-clinical trials using mice and crab-eating macaques. (Abridged)